PhaseBio

PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence

MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) announced the recent publication of the interim results from REVERSE-IT (Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial) in the New England Journal of …

PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence Read More

PhaseBio

PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab

MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), in conjunction with its financing and co-development partner for the European Union and China, SFJ Pharmaceuticals, recently announced interim results from REVERSE-IT …

PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab Read More